Medisorb naltrexone 380 mg + Oral naltrexone to Medisorb naltrexone 380 mg

Phase 3Terminated

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Alcoholism

Conditions

Alcoholism, Opiate Dependence

Trial Timeline

Aug 1, 2004 → Jan 1, 2007

NCT ID

NCT00156936

About Medisorb naltrexone 380 mg + Oral naltrexone to Medisorb naltrexone 380 mg

Medisorb naltrexone 380 mg + Oral naltrexone to Medisorb naltrexone 380 mg is a phase 3 stage product being developed by Alkermes for Alcoholism. The current trial status is terminated. This product is registered under clinical trial identifier NCT00156936. Target conditions include Alcoholism, Opiate Dependence.

What happened to similar drugs?

4 of 8 similar drugs in Alcoholism were approved

Approved (4) Terminated (0) Active (4)

✅Seroquel XRAstraZenecaApproved

✅Acamprosate or NaltrexoneMerckApproved

✅Acamprosate + PlaceboMerckApproved

✅LevetiracetamUCBApproved

🔄Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy + Naltrexone 50 mg/day + Cognitive Behavioral Therapy + Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral TherapyJohnson & JohnsonPhase 3

🔄Medisorb naltrexone 380 mg + Medisorb naltrexone 190 mgAlkermesPhase 3

🔄Medisorb naltrexone 380 mg + Oral naltrexone 50 mgAlkermesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00156936	Phase 3	Terminated	Aug 1, 2004	Jan 1, 2007	Alcoholism

Competing Products

18 competing products in Alcoholism

See all competitors

Product	Company	Stage	Hype Score
acamprosate	Johnson & Johnson	Pre-clinical	26
Topiramate and Naltrexone	Johnson & Johnson	Phase 1	29
Topiramate	Johnson & Johnson	Phase 2	35
ondansetron + cognitive behavioral therapy + topiramate + cognitive behavioral therapy + Placebo + cognitive behavioral therapy + ondansetron + topiramate + cognitive behavioral therapy	Johnson & Johnson	Phase 2	31
Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy + Naltrexone 50 mg/day + Cognitive Behavioral Therapy + Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy	Johnson & Johnson	Phase 3	40
topiramate	Johnson & Johnson	Phase 2	35
Seroquel XR	AstraZeneca	Approved	43
Quetiapine fumarate	AstraZeneca	Phase 2	35
Acamprosate or Naltrexone	Merck	Approved	43
Acamprosate + Placebo	Merck	Approved	43
SCH 900435 + Placebo	Merck	Phase 2	27
CP-866,087	Pfizer	Phase 2	35
Levetiracetam	UCB	Approved	43
levetiracetam	UCB	Phase 2	35
Nalmefene + Placebo	Lundbeck	Phase 1	18
Medisorb naltrexone 380 mg + Medisorb naltrexone 190 mg	Alkermes	Phase 3	37
Medisorb naltrexone 380 mg + Oral naltrexone 50 mg	Alkermes	Phase 3	37
Medisorb naltrexone 190 mg + Medisorb naltrexone 380 mg + Placebo matching Medisorb naltrexone 190 mg + Placebo matching Medisorb naltrexone 380 mg	Alkermes	Phase 3	37